Overview

Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)

Status:
Completed

Trial end date:
2019-11-30

Target enrollment:

Participant gender:

Summary

This study is being conducted to determine safety and effectiveness of transplanting hearts from Hepatitis C-positive donors into Hepatitis C-negative patients on the heart transplant waitlist, who will then be treated with Zepatier after transplantation.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Pennsylvania

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Elbasvir-grazoprevir drug combination